165 results on '"Bozzarelli, Silvia"'
Search Results
2. Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
3. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
4. Prognostic Value of Body Mass Index in Stage II/III Colon Cancer: Posthoc Analysis From the TOSCA Trial
5. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
6. SAT-523 Intrahepatic cholangiocarcinoma: characteristics and outcomes of patients with or without underlying liver disease
7. THU-474-YI Immunotherapy in cholangiocarcinoma: understanding the immune landscape reveals treatment response
8. Invasive IPMN relapse later and more often in lungs in comparison to pancreatic ductal adenocarcinoma
9. Unveiling the prognostic significance of malignant ascites in advanced gastrointestinal cancers: a marker of peritoneal carcinomatosis burden.
10. Pathologic tumour response to neoadjuvant therapy in resected pancreatic cancer: does it affect prognosis?
11. Aggressive Adult Pancreatoblastoma with Early Recurrence: A Case Report
12. Ampullary Cancer: Histological Subtypes, Markers, and Clinical Behaviour—State of the Art and Perspectives
13. Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study
14. Secondary Tumors of the Pancreas: A Multicenter Analysis of Clinicopathological and Endosonographic Features
15. Pancreatic Ductal Adenocarcinoma and Immune Checkpoint Inhibitors: The Gray Curtain of Immunotherapy and Spikes of Lights
16. Early Recurrence after Upfront Surgery for Pancreatic Ductal Adenocarcinoma
17. Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
18. Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications
19. Can STEreotactic Body Radiation Therapy (SBRT) Improve the Prognosis of Unresectable Locally Advanced Pancreatic Cancer? Long-Term Clinical Outcomes, Toxicity and Prognostic Factors on 142 Patients (STEP Study).
20. Immune-related adverse events and clinical outcomes in unresectable hepatocellular carcinoma: a single-institute restrospective analysis
21. Early onset metastatic colorectal cancer in patients receiving panitumumab‐based upfront strategy: Overall and sex‐specific outcomes in the Valentino trial
22. Pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous tumor: Different prognostic factors for different overall survival
23. Tumour burden score and immune‐related hepatotoxicity in patients with hepatocellular carcinoma or liver metastases treated with immune checkpoint inhibitors
24. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies
25. The dual checkpoint blockade in unresectable hepatocellular carcinoma: opportunities emerging in clinical trials
26. Implementing Pre-Therapeutic UGT1A1 Genotyping in Clinical Practice: A Real-Life Study
27. Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors
28. Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy
29. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
30. Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma
31. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial
32. Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial
33. Incidence of hepatotoxicity in patients with hepatocellular carcinoma on treatment with immune checkpoint inhibitors: impact on outcomes and tissue biomarker analysis
34. COVID‐19 and liver cancer clinical trials: Not everything is lost
35. Sa1456 COMPARISON OF DIAGNOSTIC GAINS BY NEXT-GENERATION PROFILING, CONVENTIONAL CYTOLOGY AND HISTOLOGY IN PATIENTS WITH LOCALLY ADVANCED PANCREATIC ADENOCARCINOMA FOLLOWING EUS-GUIDED BIOPSY
36. Do irinotecan (IRI) dose reductions driven by UGT1A1*28 genotyping prevent IRI-related severe neutropenia? A real-world study.
37. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question
38. Regorafenib in patients with refractory metastatic pancreatic cancer: a Phase II study (RESOUND)
39. Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2‐B3) and thymic carcinoma previously treated with chemotherapy.
40. SAT572 - Immune-related adverse events and clinical outcomes in unresectable hepatocellular carcinoma: a single-institute restrospective analysis
41. Targeted agents for second-line treatment of advanced hepatocellular carcinoma
42. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
43. Liver injury by immune checkpoint inhibitors in patients with hepatocellular carcinoma.
44. Prognostic factors and disease course in patients enrolled onto clinical trials of second-line therapy for hepatocellular carcinoma.
45. Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study
46. A phase II study of regorafenib in patients with thymic epithelial tumours previously treated with chemotherapy.
47. Efficacy of oral chemotherapy with capecitabine and temozolomide (CapTem) in metastatic neuroendocrine tumors (NETs): A single-institution experience.
48. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
49. Preoperative or Perioperative Docetaxel, Oxaliplatin, Capecitabine Gastrodoc Regimen in Patients with Locally Advanced Resectable Gastric Cancer: A Randomized Phase II Trial
50. Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.